Anticancer Activity of Alectinib through Hydroxypropyl-β-Cyclodextrin Complexation: In Vitro Evaluation on A549 Lung...

Area of Science:

• Pharmacology
• Drug Delivery
• Oncology

Background:

• Alectinib is a key treatment for anaplastic lymphoma kinase-positive non-small-cell lung cancer.
• Limited alectinib solubility hinders its therapeutic effectiveness.
• Improving alectinib's solubility is crucial for enhanced cancer treatment.

Purpose of the Study:

• To enhance alectinib's anticancer efficacy via hydroxypropyl-β-cyclodextrin complexation.
• To evaluate the antiproliferative, antimigratory, and antiangiogenic effects of the complex.
• To assess the impact of complexation on alectinib's solubility and therapeutic potential.

Main Methods:

• Synthesis of alectinib-hydroxypropyl-β-cyclodextrin inclusion complex using the kneading method.
• Characterization of the synthesized complex.
• In vitro assays including MTT, colony formation, scratch wound healing, and tube formation assays on A549 cells.

Main Results:

• The alectinib-hydroxypropyl-β-cyclodextrin complex showed significantly increased cytotoxicity compared to free alectinib.
• The complex demonstrated diminished colony formation and inhibited cell migration.
• Impaired tube formation indicated reduced antiangiogenic activity of the complexed drug.

Conclusions:

• Hydroxypropyl-β-cyclodextrin complexation improves alectinib's solubility and anticancer activity.
• This strategy offers a promising approach to enhance alectinib's therapeutic potential for non-small-cell lung cancer.
• The findings support the use of cyclodextrin complexation for optimizing drug delivery and efficacy in cancer therapy.